BRE-13: Mediterranean Diet (BRE-13)

November 11, 2026 updated by: Lisa Tussing-Humphreys, University of Illinois Chicago

BRE-13: Mediterranean Diet-A Presurgical Window of Opportunity Trial Among Women With Breast Cancer

Explore the effect of MedDiet vs. Usual Diet on circulating and breast tumor fatty acid profiles. The investigators aim to examine impact on tumor biology in newly diagnosed participants.

Study Overview

Detailed Description

Conduct a 3-week presurgical window trial among 30 women with stage I-III luminal breast cancer. Participants will be randomized 1:1 to a controlled MedDiet or an enhanced usual-care control. This study will generate critical translational data on how dietary fat composition influences tumor metabolism and immune response, informing future diet-based cancer interventions.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Lisa Marie Tussing-Humphreys, Ph.D.
  • Phone Number: 312 355 5521
  • Email: tussing@uic.edu

Study Contact Backup

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60612
        • Recruiting
        • University of Illinois at Chicago Campus
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Age ≥ 18 years;
  2. Newly diagnosed stage I-III luminal breast cancer
  3. Planned surgical resection at UI Health
  4. Ability to speak, read, write, and understand English
  5. A Mediterranean Eating Pattern for Americans (MEPA-III) score <13 indicating that they do not currently follow a MedDiet;
  6. ECOG performance status of 0 or 1.

Exclusion Criteria:

  1. Currently following a MedDiet, vegan diet, or dietary restrictions (e.g., religious, food intolerance/allergy) that preclude adoption of a MedDiet;
  2. Lack of access to a space to safely store and reheat foods items;
  3. Living in facility that provides meals;
  4. Chronic CKD stage 3+ or currently receiving dialysis treatment;
  5. History of GI surgery involving removal of part of the stomach or intestines;
  6. Type 1 or Type 2 diabetes;
  7. Autoimmune or Inflammatory disease or immunocompromised; and
  8. Cachexia.

We will not exclude other neoadjuvant treatments. Adults unable to consent Individuals who are not yet adults (infants, children, teenagers) Pregnant or breastfeeding women Prisoners

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Med Diet

Mediterranean Diet (MedDiet) is a dietary pattern characterized by a low intake of saturated fats and a high intake of unsaturated fats, with olive oil as the primary culinary fat (7, 8).

Fatty acid profile (chain length and degree of saturation) in circulation of blood, tumor tissue, and tumor interstitial fluid.

Fatty acid profile (chain length and degree of saturation) in breast tumor tissue.

Lipid availability in blood, tumor tissue, and tumor interstitial fluid.

Tumor tissue will explore the effect of MedDiet vs. Usual Diet on tumor proliferation (Ki67) and expression of NK and CD8 T cells and chylomicrons (Apo48 staining).

No Intervention: Usual Diet

Dietary fat and cancer has been conducted in preclinical models of diet-induced obesity, where high-fat diets promote tumor growth

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Aim 1a
Time Frame: 3 weeks

Fatty acid profile (chain length and degree of saturation) in blood.

3 weeks
Aim 1b
Time Frame: 3 weeks

Lipid availability in blood, tumor tissue, and interstitial fluid.

3 weeks
Aim 1c
Time Frame: 3 weeks

Fatty acid profile (chain length and degree of saturation) in breast tumor tissue,

3 weeks
Aim 2a
Time Frame: 3 weeks

peripheral blood monocyte cells from the electronic health record.

3 weeks
Aim 2b
Time Frame: 3 weeks

Tumor tissue will explore the effects on tumor proliferation (Ki67) cells.

3 weeks
Aim 2c
Time Frame: 3 weeks

Tumor tissue will explore the effects on expression of NK cells.

3 weeks
Aim 2d
Time Frame: 3 weeks

Tumor tissue will explore the effects on CD8 T cells(immunohistochemistry) cells.

3 weeks
Aim 2e
Time Frame: 3 weeks

Tumor tissue will explore the effects on chylomicrons (Apo48 staining) cells.

3 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exploratory aim a
Time Frame: 3weeks

Stool will be used to analyze gut microbiome changes using shotgun bioinformatics and downstream bioinformatics to study compositional and metabolic changes among the two study arms.

3weeks
Exploratory aim b
Time Frame: 3weeks

Stool will be used to analyze downstream bioinformatics to study compositional and metabolic changes among the two study arms.

3weeks
Exploratory aim c
Time Frame: 3weeks

Stool will be used to analyze metabolic changes among the two study arms.

3weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lisa Marie Tussing-Humphreys, Ph.D, University of Illinois Chicago Campus

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 11, 2026

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

September 1, 2028

Study Registration Dates

First Submitted

October 1, 2026

First Submitted That Met QC Criteria

October 6, 2026

First Posted (Actual)

October 9, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe